IPP Bureau
Lilly to buy Ventyx Biosciences for $1.2 billion
By IPP Bureau - January 08, 2026
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal
By IPP Bureau - January 08, 2026
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Biocon Biologics unveils three new oncology biosimilars, eyes $75 billion market opportunity
By IPP Bureau - January 08, 2026
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
GSK’s Exdensur wins Japanese nod for severe asthma
By IPP Bureau - January 08, 2026
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer
By IPP Bureau - January 08, 2026
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
By IPP Bureau - January 08, 2026
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Acesion Pharma launches Phase 2 trial for groundbreaking atrial fibrillation therapy
By IPP Bureau - January 08, 2026
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Alzheimer’s could soon be detected with a simple finger-prick
By IPP Bureau - January 08, 2026
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Rapid-acting ADHD treatment Azstarys now approved in China
By IPP Bureau - January 08, 2026
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Bayer’s Sevabertinib gets green light from FDA and China for advanced lung cancer
By IPP Bureau - January 08, 2026
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy
By IPP Bureau - January 08, 2026
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Stereotaxis scores FDA nod for groundbreaking MAGiC robotic heart catheter
By IPP Bureau - January 08, 2026
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
By IPP Bureau - January 08, 2026
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Ascletis Pharma gets FDA nod for Phase II diabetes trial of oral GLP-1 drug
By IPP Bureau - January 08, 2026
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study
By IPP Bureau - January 08, 2026
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
